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MitochondriaTen years ago we ﬁrst proposed the Alzheimer's disease (AD)mitochondrial cascade hypothesis. This hypothesis
maintains that gene inheritance deﬁnes an individual's baseline mitochondrial function; inherited and environ-
mental factors determine rates at which mitochondrial function changes over time; and baseline mitochondrial
function and mitochondrial change rates inﬂuence AD chronology. Our hypothesis unequivocally states in spo-
radic, late-onset AD, mitochondrial function affects amyloid precursor protein (APP) expression, APP processing,
or beta amyloid (Aβ) accumulation and argues if an amyloid cascade truly exists, mitochondrial function triggers
it. We now review the state of the mitochondrial cascade hypothesis, and discuss it in the context of recent AD
biomarker studies, diagnostic criteria, and clinical trials. Our hypothesis predicts that biomarker changes reﬂect
brain aging, new AD deﬁnitions clinically stage brain aging, and removing brain Aβ at any point will marginally
impact cognitive trajectories. Our hypothesis, therefore, offers unique perspective into what sporadic, late-onset
AD is andhow to best treat it. This article is part of a Special Issue entitled:Misfolded Proteins,Mitochondrial Dys-
function, and Neurodegenerative Diseases.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
As originally deﬁned, Alzheimer's disease (AD) described patients
with presenile dementia, extracellular cortical “plaques”, and intra-
neuronal “tangles” [1,2]. Subsequent work found that plaques contain
an amyloid protein, beta amyloid (Aβ), and tangles contain aggregated
tau protein [3–5]. Aβ itself is a fragment of a larger protein, the amyloid
precursor protein (APP) [6].
In order to establish AD as a bonaﬁde disease, early criteria excluded
patients with senile dementia [2,7]. Due to its commonality, senilese; APP, amyloid precursor pro-
se subunit 2; CSF, cerebrospinal
Alzheimer's type; FAD, familial
sitron emission tomography;
eimer's disease;MCI, mild cog-
mtDNA, mitochondrial DNA;
ide adenine dinucleotide; PEG,
ated receptor gamma complex
DAT, senile dementia of the
anscription 1; TFAM, transcrip-
f the outer mitochondrial mem-
folded Proteins, Mitochondrial
MS 2012, 3901 Rainbow Blvd,
1 913 588 0681.
).
ights reserved.dementia was generally considered an age-associated phenomenon,
and not a true disease. Because plaques and tangles frequently accom-
panied senile dementia, though, investigators eventually expanded
the deﬁnition to also include those with senile dementia, plaques, and
tangles [8].
Initially, an arbitrary boundary of 55, 60, or 65 years of age separated
the presenile “dementia of the Alzheimer's type” (DAT) cases from the
“senile dementia of the Alzheimer's type” (SDAT) cases [9]. From the
outset, those with SDAT vastly outnumbered those with DAT.
A small minority of the presenile DAT patients experienced clear-cut
autosomal dominant inheritance. Sequence analysis of a candidate
gene, the APP gene, in a handful of these familial AD (FAD) kindreds re-
vealed APPmutations [10]. In other families, FAD linkage studies helped
identifymutations in two related genes, PSEN1 and PSEN2 [11,12]. Their
products, the presenilin 1 and 2 proteins, contribute to a larger protein
complex, the γ secretase complex, which cleaves APP [13].
Largely based on APP mutation data, investigators proposed the
“amyloid cascade hypothesis” to explain why and how AD arises
[14,15]. The amyloid cascade hypothesis assumes that Aβ causes and
drives clinical ADby forming in the brain, disrupting function, triggering
other pathologies, and directly or indirectly killing neurons. The recog-
nized role of presenilin proteins in APP processing, aswell as Aβ's ability
to perturb cell function and viability in experimental systems, bolsters
this hypothesis [16]. While the overall principle remains unchanged
over two decades, reﬁnements have occurred, most notably in regard
to which Aβ conﬁgurationmediates the disease. Initial versions claimed
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cause AD [17].
The amyloid cascade hypothesis etiologically lumps late-onset AD
(LOAD) with FAD, and de-emphasizes potential connections between
LOAD and aging [9]. It presumes that FAD-based disease models
model LOAD. It predicts that because Aβ causes AD, removing Aβ or
preventing its formation will arrest or prevent AD.
Meanwhile, clinical efforts to better diagnose, track, and treat AD
continue to produce newdata and novel datasets. Investigators often in-
terpret their ﬁndings, which increasingly utilize new technologies such
as in vivo plaque imaging, within the context of the amyloid cascade
hypothesis.
To better unify and reconcile clinical and amyloid cascade hypothesis-
based perspectives, new AD deﬁnitions were recently proposed [18–20].
While many believe that this will help us to better understand and treat
AD, it is important to recognize that this view is not universal and alterna-
tive perspectives exist. This reviewwill discuss recent AD biomarker data,
diagnostic criteria, and clinical trial results fromtheperspective of a differ-
ent AD hypothesis, the “mitochondrial cascade hypothesis” [21–27].
2. The mitochondrial cascade hypothesis: basis and overview
We ﬁrst proposed the ADmitochondrial cascade hypothesis in 2004
[24]. It consists of three main parts (Fig. 1). First, the mitochondrial cas-
cade hypothesis maintains that gene inheritance deﬁnes an individual's
baseline mitochondrial function. In this respect, both mothers and fa-
thers contribute to their offspring's AD risk, but because mitochondrial
DNA (mtDNA) is maternally inherited mothers contribute more.
Second, inherited and environmental factors determine the rate at
which age-associated mitochondrial changes develop and manifest. If,
as data suggest, declining mitochondrial function or efﬁciency drives
agingphenotypes [28–30], then greatermitochondrial durability should
associate with slower brain aging and lesser mitochondrial durability
should associate with faster brain aging.
Third, an individual's baselinemitochondrial function and functional
change rate inﬂuences their AD chronology. Those with low baseline
function and fast rates of mitochondrial decline will develop symptoms
and ADhistology changes at younger ages than thosewith high baseline
function and slow rates of mitochondrial decline. Those with less ex-
treme combinations, for example those with low baseline function
and slow rates of mitochondrial decline, or with high baseline function
and fast rates of mitochondrial decline, will develop symptoms and AD
histology changes at intermediate ages.Fig. 1. Themitochondrial cascadehypothesis. This hypothesismaintains that individuals start ou
function declines at a particular rate. Eventually, mitochondrial decline surpasses a threshold
changes in APP, sAPPα, or Aβmay ormay not further inﬂuencemitochondrial function. In FAD,
may end up activating pathways that are also activated in LOAD.Themitochondrial cascadehypothesis incorporates, links, and builds
upon previously proposed hypotheses and concepts. The idea that
mtDNA inheritance, through effects on mitochondrial function, inﬂu-
ences AD riskwas originally developed by Parker [31,32]. Several inves-
tigators postulated that somatic mtDNA mutations, accumulating over
a person's lifespan, inﬂuence aging [33–35]; Wallace, in particular,
championed the idea that somatic mtDNA mutations could cause AD
[34]. The proposition that mitochondria drive aging certainly dates
back decades [36]. Regarding AD, contributory or even causal roles for
speciﬁc mitochondrial defects were envisioned by a number of investi-
gators including, but not limited to, Blass, Gibson, Sims, Hoyer, Parker,
Beal, Castellani, Smith, and Perry [37–48].
Our hypothesis unequivocally states that in sporadic, late-onset AD,
mitochondrial function affects APP expression, APP processing, or Aβ
accumulation. This possibility had already been suggested by data
from other laboratories [21]. By the late 1990's at least three studies
reported that toxin-induced mitochondrial dysfunction pushes APP
processing towards Aβ production [49–51]. Those data, in conjunction
with data showing that AD subject mitochondrial transfer increases
neuroblastoma cell Aβ production (discussed in greater detail in the
next section) [52], led us to speculate that even if an amyloid cascade
truly exists, mitochondrial function triggers it.
We were further impressed by the fact that mitochondrial dysfunc-
tion could potentially produce other AD-associated molecular phenom-
ena, such as increased oxidative stress markers [53,54]. Additionally,
others had already shown that mitochondrial dysfunction affects tau
phosphorylation [55,56], and can induce inﬂammation [57]. For all
these reasons, we felt that as far as LOADwas concerned, diverse inves-
tigations suggested that mitochondria could initiate and drive multiple
AD pathologies.
Perceived weaknesses in the amyloid cascade hypothesis also en-
couraged us to formulate the mitochondrial cascade hypothesis. On an
abstract level, the amyloid cascade hypothesis did not address how in-
creased Aβ production or decreased Aβ removal spontaneously arises
in LOAD. Either possibility could conceivably occur as a consequence
of genetic traits, or develop due to a random, prion-like conformational
change, but to date why Aβ dynamics change after many decades of ho-
meostasis remains unanswered.
On a more concrete level, the amyloid cascade hypothesis did not
address why particular biochemical defects appear outside the brain,
for example in ﬁbroblasts and platelets [21], of AD subjects. Perhaps
such changes are directly caused by undetected systemic Aβ produc-
tion, or perhaps they simply represent indirect consequences of havingtwith a particular level ofmitochondrial function, and that each individual'smitochondrial
and triggers the histologic changes associated with AD. The question mark indicates that
if APP, sAPPα, or Aβ homeostasis changes inducemitochondria dysfunction, these changes
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ical activity. To us, though, such explanations appeared unlikely. The
mitochondrial cascade hypothesis, therefore, speciﬁcally attempted to
account for AD's late-life onset, as well as the potentially systemic na-
ture of AD's biochemical changes.
The mitochondrial cascade hypothesis assumes that although LOAD
and autosomal dominant FAD might share some important mecha-
nisms, key differences will nevertheless exist. Both LOAD itself and
FAD models feature mitochondrial dysfunction [21], so we expect
most if not all mechanistic overlap will occur downstream of that step.
How mitochondrial dysfunction arises, though, will differ. In LOAD,
age-associated changes in mitochondrial function, which mtDNA may
mediate, will prove critical. In autosomal dominant AD, changes in
APP or its processing will prove critical. To this end, accumulating data
certainly do suggest that APP and Aβ, as well as the entire γ-secretase
complex, physically associatewithmitochondria and can effect changes
in mitochondrial function [58–67].
One of our goals was to speciﬁcally link aging, AD, and AD histol-
ogy changes. To accomplish this we adopted an already existing
mitochondria-centric aging theory [68–70], and extended it to possibly
explain how aging might account for AD and AD histology. We felt that
this was necessary because with advancing age AD prevalence and inci-
dence skyrocket [71–75]. Indeed, among some geriatric demographics
more people have AD than thosewho don't have it. AD histology changes
are found even more frequently [76–78]. In pointing this out we do not
claim that everyone, should they live long enough, will develop AD as
exceptions to this statement likely occur [79]. Rather, to our view those
who survive to very advanced ages without developing AD signs, symp-
toms, or histology changes are the exceptions, and those who do develop
these changes represent the norm.
One question that occasionally arises in regard to our hypothesis is
whether it classiﬁes AD as a disease, or simply as brain aging. This ques-
tion perhaps warrants nuanced consideration rather than a categorical
answer. Existing data suggest that mitochondrial function declines
throughout much of adulthood and that adaptive changes, at least ini-
tially, mitigate this decline [47,80–82]. While compensation remains
adequate, symptoms do not manifest. With enough decline, however,
adequate compensation becomes impossible. Therefore, two types of
brain aging likely exist, compensated brain aging and uncompensated
brain aging. According to our hypothesis, symptomatic AD coincides
temporally with the stage of uncompensated brain aging. Whether
uncompensated brain aging represents a disease or a stage of aging,
though, doesn't really matter to those experiencing it.
Perhaps more than any other single reason, in developing the mito-
chondrial cascade hypothesis we were guided by our experience with
cytoplasmic hybrid (cybrid) cell lines generated through the transfer
of AD subject mitochondria to mtDNA-depleted neuroblastoma and te-
ratocarcinoma cell lines [21]. Belowwe discuss this cybrid work, as well
as other relevant research published since we ﬁrst proposed the mito-
chondrial cascade hypothesis.
3. Support for the hypothesis
In 1990, Parker et al. showed reduced cytochrome oxidase (COX) ac-
tivity in AD subject platelets [44]. This defect was later demonstrated in
AD subject brains [83–86]. As neurodegeneration and brain Aβ could
not easily explain reduced platelet COX activities, Parker considered a
potential genetic basis for this phenomenon [31,44]. Because LOAD
does not show clear Mendelian inheritance, mtDNA does not follow
Mendelian rules, and COX contains mtDNA-encoded subunits, the pos-
sibility of an mtDNA contribution seemed particularly attractive. To
test this, a cybrid approach was used.
The cybrid technique, developed in the 1970's [87], assesses mtDNA
functional correlates. In this technique, one transfers the cytosolic con-
tents of a donor cell, usually a platelet or enucleated cytoplast, to a nucle-
ated host cell [88,89]. Most transferred components degrade over time ordilute as the host cell divides, except formtDNA locatedwithin donormi-
tochondria. This exogenous mtDNA replicates, generates respiratory
chain subunits, and inﬂuences respiratory chain function.
Fig. 2 illustrates the general protocol used to generate our cybrid cell
lines.Weﬁrst removed the endogenousmtDNA from two different neu-
ronal lines, the SH-SY5Y neuroblastoma and NT2 teratocarcinoma cell
lines. Next, we isolated platelets from subjects with and without AD.
Transferring platelet mitochondria to the mtDNA-depleted neuroblas-
toma and teratocarcinoma lines repleted their mtDNA, and created
cybrid lines whose mtDNA derived from an AD or age-matched control
subject. Mean COX activity was lower in cybrid lines containing AD sub-
jectmtDNA than itwas in cybrid lines containing control subjectmtDNA
[90,91]. Based on this, we concluded that mtDNA at least partly deter-
mines low COX activity in AD.
The cybrid lines containing AD subjectmtDNA, the “AD cybrids”, dif-
fered from the control subject-generated “control cybrids” in other
ways; results from 18 different AD cybrid studies were recently summa-
rized elsewhere [21]. AD cybridmitochondrial was relatively depolarized,
smaller on average, and less able to buffer calcium. AD cybrids showed
decreased ATP and increased oxidative stress, stress signaling, and apo-
ptosis. Interestingly, AD cybrid Aβ levels also increased.
More recently, cybrid approaches revealed mitochondrial deﬁcien-
cies in subjects with mild cognitive impairment (MCI) [92,93]. Clinical-
ly, MCI subjects exhibit objective cognitive deﬁcits or decline, may
struggle to complete previously routine activities, but essentially retain
independent function [94–96]. Most progress and are subsequently di-
agnosed with AD, so in many MCI arguably represents very early AD
[97]. Two studies in which “MCI cybrid” lines were generated through
transfer ofMCI plateletmitochondria tomtDNA-depleted cells observed
low mean COX activity and other downstream molecular changes
[92,93]. This suggests that compared to cognitively intact individuals,
individuals in the earliest clinically detectable stage of AD already
show reduced mitochondrial function.
We recently analyzed glycolysis and respiratory ﬂuxes in AD, MCI,
and control cybrid cell lines [93]. The AD andMCI lines showed reduced
basal oxygen consumption, which suggests reduced respiratory ﬂux.
This was despite the fact that AD and MCI respiration was relatively
uncoupled, or less efﬁcient, than control cybrid respiration. AD and
MCI cybrid glycolysis ﬂuxes were also relatively lower, a somewhat un-
expected ﬁnding as cultured cells typically show inverse respiration–
glycolysis relationships [98]. Redox changes may explain this paradox
(Fig. 3). NAD+/NADH ratios in AD and MCI cybrids were lower than
they were in control cybrids; this probably reﬂects compromised respi-
ratory function. A falling NAD+/NADH ratio, though,would predictably
reduce glycolysisﬂux as glycolysis rates andNAD+/NADH ratios direct-
ly correlate. This ﬁnding provides potential insight into why respiration
and glucose utilization both decline in AD subject brains [99–101].
AD and MCI cybrid cell lines successfully model numerous patholo-
gies observed in AD andMCI subject brains (Table 1).When considering
this it is important to keep in mind several points. First, in AD and MCI
cybrids the observed changes most likely arise from changes in mito-
chondrial function. Second, the mitochondria used to generate these
cybrid lines derive not from subject brains, but from subject platelets,
which implies that mitochondrial dysfunction in AD and MCI subjects
exists independent of Aβ or neurodegeneration. Third, AD and MCI
cybrid molecular changes persist in culture, thereby suggesting that
AD and MCI subject mtDNA differs from control subject mtDNA.
Wedonot yet knowexactly howmtDNA inADandMCI cybrids differs
from mtDNA in control cybrids, but differences between AD and control
subject mtDNA certainly occur. MtDNA from AD subject brains exhibits
excess oxidative damage anddeletions [47,102–105]. Some studies report
that AD subject brains and lymphocytes show increased heteroplasmic
mutation levels [106–108]. In aggregate, AD subject brains and blood
cells contain less PCR-ampliﬁable mtDNA [47,105,109–111].
These differences presumably reﬂect somatic, or acquired, changes.
While the mitochondrial cascade hypothesis assumes that these
Fig. 2. The cybrid technique. An expandable cell line is treatedwith enough ethidiumbromide to interferewithmtDNA replication, but not enough to prevent nuclear DNA replication. This
depletes the cell line's endogenousmtDNA (shownby the absence of the redmtDNA circlewithin themitochondrion in the top row), removes itsmtDNA-encoded subunits (shown by the
absence of the red rectangles within themitochondrion in the top row), and generates a respiration-incompetent cell called a ρ0 cell. Incubating ρ0 cells with platelets in the presence of
polyethylene glycol (PEG) allows platelet and ρ0 cell cytosols to mix. Platelet mitochondria contain mtDNA (shown as a green circle within themitochondrion in the bottom row), which
populates the ρ0 cell mitochondria, generates mtDNA-encoded respiratory chain subunits (shown as green rectangles within the mitochondrion in the bottom row), and restores
respiratory competence. The new cybrid cell now containsmtDNA from the platelet donor, mtDNA-encoded respiratory chain subunits that match those of the platelet donor, its original
nuclear DNA, and its original nuclear-encoded respiratory chain subunits.
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inheritance as well as the inheritance of genes that maintain mtDNA
and mitochondrial function also play an important role.
Several investigative lines argue that mtDNA inheritance could
inﬂuence AD risk. First, epidemiologic studies ﬁnd that although both
parents contribute to an individual's AD risk [112], mothers contribute
more than fathers [113–116]. Second, maternal inheritance mayFig. 3. Proposed mechanism through which respiratory decline can reduce glucose
utilization. In the presence of respiratory chain impairment, which in AD could result
from reduced COX activity, NADH generated within the mitochondria during the Krebs
cycle cannot be oxidized. Increased NADH in the mitochondrial compartment, in turn,
transmits indirectly to the cytosolic compartment. Shifting the cytosolic NAD+/NADH
ratio towardsNADH slows glycolysis, since glycolysis rates are to some extent determined
by the cytosolic NAD+/NADH ratio. Reductions in both respiration and glycolysis ﬂuxes
result in less ATP production, and increase the cell ADP/ATP ratio.speciﬁcally affect mid-life memory performance [117]. Third, particular
mtDNA haplogroups or haplotypes reportedlymodify AD risk, although
this remains uncertain as inconsistencies exist between different
haplogroup and haplotype association studies [118–128].
Endophenotype studies further suggest that maternal inheritance
uniquely contributes to AD risk. Endophenotypes are disease-associated
characteristics, traits, or markers observed in the absence of a full disease
state. Maternal inheritance appears to determine several AD endopheno-
types. The ﬁrst maternally-determined AD endophenotype was reported
byMosconi et al. in 2007 [129]. This study found that cognitively normal,
middle-aged children of AD mothers, but not AD fathers, show reduced
cerebral glucose utilization on ﬂuorodeoxyglucose positron emission to-
mography (FDG PET). Subsequent studies found that the cognitively in-
tact children of AD mothers, relative to the cognitively intact children of
AD fathers, show greater degrees of age-associated brain atrophy, faster
rates of longitudinal brain atrophy, increased Aβ plaque deposition,Table 1
Comparison of AD brain and AD cybrid bioenergetic-related phenomena.
Differences in AD versus control brains also observed in AD versus control cybrid cell
lines
Low cytochrome oxidase Vmax activity
Increased oxidative stress markers
Increased Aβ
Activated stress signaling pathways
Reduced PGC1αmRNA
Reduced HIF1α protein
Activated apoptotic signaling
NFκB activation
Overall increased COX2 protein
Reduced mTOR protein
Increased mitochondrial ﬁssion
Decreased SIRT1
Decreased O2 consumption
Decreased glucose utilization
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CSF Aβ changes [130–137]. As mentioned above maternal inheritance
also inﬂuences memory test performance in middle-aged individuals,
since in some demographics individuals with AD mothers do not score
as well on memory tests as individuals with AD fathers [117]. A growing
number of databases using different approaches currently report mater-
nal inheritance-associated AD endophenotypes [138–141].
We recently measured platelet mitochondria COX activity in cogni-
tively normal adult children of AD patients [142]. We deﬁned three
subject groups, those with an AD-affected mother, an AD-affected
father, or un-affected parents. Mean COX activity was lower in subjects
with AD-affectedmothers than it was in the other two groups.Maternal
inheritance, therefore, also associates with a systemic biochemical
endophenotype.
Among nuclear genes, translocase of the outer mitochondria mem-
brane 40 homolog (TOMM40) may play a major role [143–156]. This
gene's product mediates the transfer of nuclear-encoded mitochondrial
proteins from the cytoplasm to themitochondria. The TOMM40gene lo-
calizes to 19q13.2, by far themost strongly associated LOAD locus [157].
The APOE gene also resides at 19q13.2, and approximately 20 years ago
investigators concluded that APOE isoforms mediate the association
[158,159]. The TOMM40 and APOE genes, though, sit remarkably close
to each other and linkage disequilibrium occurs between particular
TOMM40 and APOE alleles.
The most studied linkage disequilibrium is the one deﬁned by
APOE4 and the TOMM40 rs10524523 polyT polymorphism [143,160].
The TOMM40 rs10524523 polyT polymorphism, located in intron 6,
demonstrates substantial variation. In one classiﬁcation scheme, polyT
stretches of 19 or less constitute a “short” allele, polyT stretches of
20–29 deﬁne a “long” allele, and polyT stretches of 30 ormore represent
a “very long” allele. In Caucasian populations, the TOMM40 long allele
typically segregates with the AD-associated APOE4 allele.
On a pure genetic level, linkage disequilibrium between particular
TOMM40 and APOE alleles confounds AD-gene association assumptions,
and makes it difﬁcult to know whether TOMM40, APOE, or both genes
truly mediate AD risk [161]. While some investigators argue that
TOMM40will not turn out to play a role in AD [162,163], from a strict as-
sociation perspective it does appear that the TOMM40 gene, and by ex-
tension its protein product, could potentially impact LOAD. The APOE
gene product, interestingly, also appears to inﬂuencemitochondrial func-
tion [164–167]. It will be interesting to see how this story evolves.
Polymorphisms in other nuclear genes, for example transcription
factor A of the mitochondria (TFAM), associate with AD risk in some
studies [168–170]. Associations such as these, though, are currently
considered preliminary rather than conclusive. Also, it is important to
keep in mind that respiratory chain holoenzymes contain multiple sub-
units. Complexes I, III, IV, and V contain both mtDNA and nuclear DNA-
encoded subunits. This could obscure the contributions of individual re-
spiratory chain genes. For example, we recently surveyed the breadth of
polymorphic variation in the 13 COX subunit genes [171]. Among 27 in-
dividuals in which the exons of each COX gene were sequenced, no two
individuals exhibited an identical composite genotype. We also se-
quenced the three mtDNA COX genes in ﬁfty subjects. 20% had at least
one non-synonymous polymorphism, and synonymous polymorphisms
were even more common.
These and other data in this section argue inheritance determines an
individual's baseline mitochondrial function and durability, and mater-
nal inheritance plays a greater role than paternal inheritance [30]. This
in turn inﬂuences AD-relevant phenomena includingmemory, bioener-
getics, amyloidosis, and brain atrophy. Another assumption, that declin-
ing mitochondrial function occurs with advancing age, is generally
accepted [35,80,81].
Data also argue that mitochondria directly inﬂuence other AD-
associated pathologies, and particularly APP and Aβ homeostasis. Cell
culture experiments showing that mitochondrial function and cell
bioenergetics affect APP processing were previously mentioned [49–52,172], and functional imaging data consistent with this principle
were recently published [173]. mtDNA polymorphisms inﬂuence Aβ
production and plaque deposition in mice that express an APP trans-
gene [174]. Further, crossing mutant APP-PS1 transgenic mice that
overproduce Aβwith COX-deﬁcient mice dramatically lowers Aβ levels
[175,176]. At face value this ﬁnding might seem inconsistent with the
mitochondrial cascade hypothesis, but in light of recent studies that de-
ﬁne actual Aβ–AD temporal relationshipswe believe that these data are
quite consistent with our hypothesis. We discuss this in detail in the
next section. Regardless, these mouse studies strongly underscore the
presence of a mitochondria–Aβ nexus.
Finally, we note recent reports that show brains normally produce
Aβ, and that Aβ production rates correlate with normal physiologic
states such as sleep–wake cycles [177–184]. Overall, we feel we can
conﬁdently state that APP and Aβ homeostasis are exquisitely regulated
processes, and bioenergetic metabolism regulates these processes.
4. Biomarker data: relationships and implications
Biomarkers consist of measurable biological endpoints, and ideally
provide insight into disease-related phenomena. They can facilitate dis-
ease diagnosis, track disease progression, quantify disease risk, demon-
strate treatment target engagement, or predict treatment response.
Current popular AD biomarkers include FDG PET; structural magnetic
resonance imaging (MRI); amyloid PET; and CSF Aβ, tau, and phosphor-
ylated tau levels.
FDG PET quantiﬁes brain glucose utilization. Regional reductions in
brain glucose utilization occur with aging and to a greater extent in
MCI and AD [185–193]. Glucose utilization and synaptic density directly
correlate, so to some extent FDG PET reﬂects synaptic integrity [194].
WithMRI, investigators canmeasure and track brain global and regional
brain volumes. Regional reductions occur during aging, and becomemore
pervasive with MCI and AD [195,196]. Amyloid PET takes advantage of
radiolabeled ligands that bind ﬁbrillar Aβ, reveal the presence or absence
of amyloid plaques, and estimate plaque burden [197–200]. Relative to
control subjects, MCI and AD subjects typically show low CSF Aβ, high
total tau, and high phosphorylated tau levels [201,202]. Some feel that
CSF Aβ falls because of disease-associated solubility changes, or because
it begins to stick to parenchymal plaques [203]. Tau rises, some claim, as
increasing numbers of dead or dying neurons release their intracellular
contents. The actual underlying mechanism, though, to some extent
remains uncertain [204].
In 2010, Jack et al. summarized biomarker temporal relationships
[205]. Their timeline states that in individuals who develop AD, Aβ
plaque deposition and reduced CSF Aβ occur ﬁrst. Next, CSF tau levels
rise. These changesmanifest years before clinical signs or symptoms de-
velop. Later on hippocampal atrophy appears, followed shortly thereaf-
ter by memory decline and eventually dementia. Full progression from
Aβ changes to clinical decline takes approximately 10 to 20 years.
The amyloid cascade hypothesis interprets this biomarker timeline
in the following way. Aβ forms and accumulates within the brain. It
damages and kills neurons, which spill tau. Eliminating a critical mass
of neurons shrinks the brain, disrupts structural and functional integrity,
and causes clinical symptoms.
The amyloid cascade hypothesis further assumes that reduced FDG
PET glucose utilization follows Aβ changes but precedes clinical
changes. Also, Aβ plays a double role, since it acts as a biomarker of
thedisease, aswell as causes the disease. Indeed, the “upstream”Aβ bio-
markers presumably drive changes in the “downstream” CSF tau, MRI,
and FDG PET biomarkers [20]. Aβ biomarkers, therefore, indicate the
presence of ADwhile the CSF tau,MRI, and FDG PET biomarkers indicate
the presence of Aβ-induced neurodegeneration.
The mitochondrial cascade hypothesis, on the other hand, does not
assume that Aβ drives the other biomarker changes. Our hypothesis,
therefore, can accommodate a growing realization that for many sub-
jects with suspected AD, or who have an increased risk of developing
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tentially precede upstream biomarker changes [206–213]. Also, the fact
that Aβ accumulates for over a decade before symptoms arise [214], a
ﬁnding that infers brains tolerate Aβ reasonably well, does not chal-
lenge our hypothesis. To us, Aβ may damage the brain a lot, a little, or
not at all.
Moreover, as plaqueprevalence riseswith age regardless of the pres-
ence or absence of dementia [215], we believe that it makes sense to
view Aβ biomarkers primarily as biomarkers of brain aging. Over a
given time period subjects with positive Aβ biomarkers will more likely
develop cognitive decline than subjects with negative Aβ biomarkers
not because positive Aβ biomarkers necessarily indicate AD, but be-
cause positive Aβ biomarkers indicate more advanced (beyond what
is inferred when no Aβ biomarkers are present) brain aging.
Recent data indicate that plaque deposition essentially occurs during
the run-up to clinical AD [216,217]. Plaque formation rates also vary
over time [217]. After a period of rapid accumulation, plaque deposition
gradually slows and by the time that symptoms manifest plaque depo-
sition is essentially done [20,205,218]. According to our hypothesis, Aβ
deposition temporally coincides with an asymptomatic stage of com-
pensated brain aging (a period during which strained physiologic or
molecular infrastructures are essentially maintained and clinical integ-
rity persists), as opposed to a symptomatic stage of uncompensated
brain aging (a period duringwhich strained physiologic ormolecular in-
frastructures are not maintained and clinical deterioration ensues)
(Fig. 4).
We propose that the following explanation applies. Under conditions
of mild bioenergetic stress the brain becomes relatively hypermetabolic.
Bioenergetic hypermetabolism, in turn, increases Aβ production. As bio-
energetic stress worsens, the brain shifts from a state of bioenergetic
hypermetabolism to one of hypometabolism, and Aβ production falls.
Consistent with this view, data suggest that normal age-related CSF
Aβ levels vary with age. Studies of non-demented individuals report
that while CSF Aβ levels seem to decline during young adulthood, during
late mid-life CSF Aβ levels may actually slightly increase [219,220]. Also,
emerging data fromFDGPET and cerebral perfusion studies showglucose
utilization and cerebral blood ﬂow may regionally increase around the
time that plaque deposition begins [221,222]. This scheme further
ﬁts, we feel, with studies of AD subject brains that show inter andFig. 4. Themitochondrial cascade hypothesis and Aβ accumulation.When age-associatedmitocho
During this period of bioenergetic compensation, Aβ production increases and Aβ accumulates.
compensate and bioenergetic-related parameters such as mitochondrial mass down-regulate. Dueven intra-neuron variations in speciﬁc mitochondrial mass markers
[47,105,223,224].
Mice engineered to overproducemutant APP and PS1 proteins in the
setting of less COX holoenzymemay provide additional insight into this
issue. The brains of these mice show reduced plaque deposition, less ﬁ-
brillar Aβ, and less oxidative stress than APP–PS1 mice that can freely
produce COX [175,176]. We wonder whether the COX problem in
these mice models a COX defect more severe than the one modeled by
our AD cybrid model [52,172], and produces a hypometabolic environ-
ment while our AD cybrids produce a hypermetabolic environment.
Finally, we predict that falling Aβ CSF levels reﬂect falling Aβ pro-
duction more than it reﬂects decreased solubility or increased incorpo-
ration into plaques. Mathematical simulations based on the amyloid
cascade hypothesis and other studies suggest otherwise, and argue
that during the course of AD Aβ production rates do not decline
[203,225]. The AD symptomatic period, however, can last over a decade
[226]. Minimal ﬁbrillar Aβ deposition occurs during this time [214,217],
CSFAβ levels remain low [201,205], and Aβ does not appreciably shift to
the blood compartment [227,228]. If Aβ production rates do not decline
during this time, then where does all the Aβ go?
5. New AD deﬁnitions: relationships and implications
Until recently, research involving AD subjects almost exclusively uti-
lized the 1984 McKhann criteria [229]. Under these criteria, only clini-
cally demented individuals could receive an AD diagnosis. However,
subsequent research revealed that non-demented subjects with objec-
tive cognitive decline often progress to a dementia syndrome and an
AD diagnosis. TheMCI designation captured these subjects [94–96]. Addi-
tional research also suggested that relative to individuals with no subjec-
tive cognitive complaints, elderly individuals with subjective cognitive
complaints are more likely to develop AD [193,230–233].
Autopsy studies reveal at the time of death, brains from cognitively
normal individuals frequently contain plaques [77,234–237]. More re-
cently, technology advances make it possible to identify plaques in liv-
ing subjects with fully preserved cognition, subjective cognitive
impairment, MCI, and AD [197,198,200,238,239]. To take advantage of
biomarker advances, and to speciﬁcally identify those in the earliest
stages of AD or at the highest risk of AD, new diagnostic criteria werendrial decline ﬁrst begins, neurons compensate by pushing their bioenergetic infrastructures.
As age-associated mitochondrial decline progresses, neurons can no longer bioenergetically
ring this hypometabolic period, Aβ production decreases.
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siders Aβ an “upstream” biomarker [20]. Accordingly, the presence of
Aβ plaques or low CSF Aβ implies the presence of AD, even in non-
demented subjects.
“Prodromal” AD applies to subjects with Aβ changes and MCI [240].
“Preclinical” AD applies to subjects with Aβ changes and either fully
normal cognition or questionable cognitive changes that don't quite jus-
tify an MCI clinical diagnosis [20]. These expanded criteria dramatically
increase the number of elderly that qualify for an AD diagnosis, or at
least some form of it; one literature-based analysis concludes 85% of
those over 85 meet at least one of the new AD criteria [26].
The mitochondrial cascade hypothesis perspective differs some-
what. Because we do not assume Aβ causes AD, we would not make it
the sole deﬁning AD diagnostic criterion. After all, many with plaques
will remain asymptomatic for years or even decades, and perhaps
some will never develop symptoms [241]. Further, plaque deposition
may coincide temporally with a period of compensated brain aging,
and data argue that symptoms generally manifest only after plaques
stop forming (Fig. 5) [205,216,217]. In the absence of symptoms or
signs, therefore, using the presence or absence of plaques to deﬁne
stages of brain aging, as opposed to AD, seems reasonable.
In essence, the mitochondrial cascade hypothesis sees plaque
deposition as technically marking one's passage through brain aging,
as opposed to one's passage into AD. According to our hypothesis, in
asymptomatic individuals plaques indicate a higher AD risk (or at
least a higher risk of developing symptomatic AD) as their presence in-
dicates a more advanced state of brain aging.
Lastly, it is worth noting that at least some elements of cognitive de-
cline evolve throughout adulthood [195,242–245]. Cognitive speed and
multitasking abilities, for example, become less robust with advancing
age. These changes typically manifest at ages younger than those at
which plaque deposition typically begins. The amyloid cascade hypoth-
esis [14,15], in conjunction with the newly designated preclinical AD
category [20], necessarily infers that cognitive changes that arise before
plaques appear are etiologically unrelated to cognitive changes that
arise after plaques appear. Under themitochondrial cascade hypothesis,
pre-plaque and post-plaque cognitive changes can potentially share a
common etiology. For this reason, we believe that our hypothesis better
accommodates data that argue early adult cognitivemarkers predict AD
risk long before plaques and probably Aβ changes occur [246,247].Fig. 5. Aβ accumulation and cognitive decline timelines. Before notable cognitive decline comm
decline begins, Aβ accumulation has virtually ceased.6. Therapeutic development: implications
If Aβ initiates and sustains an AD-speciﬁc cascade, removing it or
preventing its creation would ideally arrest onset or progression. In
one human study, a vaccine to Aβ did reduce plaque burden, a remark-
able technical achievement [248,249].While safety concerns caused this
trial to terminate prematurely, subsequent clinical analyseswere at best
unimpressive [250,251].
Trials featuring intravenous infusions of antibodies to Aβ failed to
meet their primary endpoints [252]. One of these antibodies, which to
date has not yet reported any post-hoc evidence of clinical efﬁcacy in
its phase 3 trials, appears to reduce plaque burden [253]. The other
did not show a straightforward reduction in plaque burden, but despite
this a subsequent alternative analysis argued that clinical effects should
not be ruled out and called for further studies [254].
A γ secretase inhibitor did make it to phase III testing, but safety is-
sues and accelerated decline in the treatment group brought this trial to
an early end [255]. A drug intended to modify γ secretase activity sim-
ilarly failed [256]. An agent claimed to inhibit Aβ oligomer formation
did not meet its primary endpoint and further development was
discontinued [257,258].
Several explanations could explain these generally disappointing
results [252]. Perhaps the underlying premise, that Aβ both initiates
and sustains an AD-speciﬁc cascade, is wrong. Maybe the attempted in-
terventions did not adequately engage their target, or investigators en-
rolled toomanymisdiagnosed subjects. It is also possible that Aβ-based
approaches will work in some populations but not in others. Because all
reported trials studied symptomatic AD subjects whose brains, it is pos-
tulated, may already contain critical amounts of Aβ-induced damage,
some investigators now believe that the wrong subjects were tested.
According to this reasoning, Aβ-based approaches might prevent
asymptomatic or barely symptomatic preclinical AD subjects from
progressing to symptoms [252], despite the fact that these approaches
appear to accelerate, not impact, or at best very minimally slow symp-
tomatic subject progression.
Future studies, therefore, will probe Aβ-based interventions in sub-
jects meeting the new preclinical AD criteria [20]. As people meeting
preclinical AD criteria may remain cognitively stable for many years
[205,214], these trials will take a long time to complete. An alternative
design will test Aβ-based interventions in asymptomatic FAD subjectsences, Aβ accumulation initiates, accelerates, peaks, and decelerates. By the time cognitive
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sonably predictable [259,260].
The mitochondrial cascade hypothesis, though, predicts Aβ-based
interventions failed not because these trials enrolled the wrong pa-
tients, but because Aβ does not cause LOAD. Further, our hypothesis
predicts that even if Aβ-based interventions turn out to beneﬁt FAD pa-
tients, beneﬁts may not extrapolate well to LOAD because LOAD and
FAD cascades potentially differ.
As Aβ-based “secondary prevention trials” begin in preclinical AD
subjects, we wonder if nature in some way has already conducted
such a trial. We now know from biomarker studies that brain amyloid-
osis burns itself out before clinical signs and symptoms emerge [217]. To
us, this suggests that Aβ-based interventions designed to remove or
prevent Aβ from accumulating before this process naturally stops on
its own will prove superﬂuous and, therefore, ineffective. The fact that
the amyloid tap turns itself off before clinical changes appreciably man-
ifest, we feel, also argues against the idea that Aβ perpetuates itself in a
prion-like fashion [261].
While themitochondrial cascade hypothesis perspective assumes that
removing Aβwill transform the course of neither brain aging nor AD, the
presence of a mitochondrial–APP–presenilin nexus suggests that drugs
that modify this nexus may yet modify AD. γ secretase inhibition, after
all, did accelerate cognitive decline [255]. Trials of β secretase inhibitors
still need to play out, especially since inhibiting β secretase-mediated
APP cleavage should change levels of APP and its α secretase-generated
sAPPα product. Altering levels of APP and of sAPPα, a growth factor
[262], may impact AD more than altering Aβ levels.
In general, we feel that removing Aβ from the brains of LOAD pa-
tients will only help to the extent that Aβ toxicity contributes to
LOAD. If Aβ contributes substantially removing it may help substantial-
ly, but if it contributes a little or not at all, then removing Aβwill help a
little or not at all. We suspect the latter possibility will prove to be the
case, and that removing Aβ will not actually remove the cause of AD
but instead an epiphenomenon of aging. Finally, as we believemitochon-
drial dysfunction initiates LOAD, we would instead advocate developing
mitochondrial or bioenergetic medicine approaches for the treatment of
LOAD [263–266]. If correct, we believe such approaches will beneﬁt
both asymptomatic and symptomatic individuals. We therefore think
that it still makes sense to enroll AD subjects in AD trials.
7. Conclusions
The mitochondrial cascade hypothesis offers unique AD perspectives.
At the clinical level, it tends to lump rather than split age-associated and
AD-associated cognitive changes. At the etiological level, our hypothesis
tends to split rather than lump LOAD and FAD. Accordingly, we believe
that FAD's unique genetics etiologically distinguishes FAD from LOAD
more than it links FAD to LOAD.
The mitochondrial cascade hypothesis sees Aβ as a marker of brain
aging, and not AD's singular cause. Because of this, we would not solely
equate the presence of brain Aβ changes with the presence of AD, and
we would not universally consider the Aβ deposition process as a dis-
ease process. According to our hypothesis, Aβ marks a continuum be-
tween brain aging and AD, as opposed to a unique and age-unrelated
event. In some ways, therefore, brain aging and LOAD also represent a
continuum.
The mitochondrial cascade hypothesis proposes changes in mito-
chondrial function changeAβ homeostasis. Early on, thesemitochondri-
al changes increase Aβ production and cause it to accumulate. Later on,
as mitochondrial dysfunction surpasses a threshold Aβ production and
accumulation decline.
Because Aβ is considered a consequence of brain aging as opposed to
the cause of a disease, we predict that targeted removal of brain Aβwill
only beneﬁt AD patients to the extent Aβ mediates brain damage. We
further predict that targetedAβ removalwill beneﬁt asymptomatic sub-
jects to the same extent it beneﬁts symptomatic subjects.According to our hypothesis, arresting brain aging will arrest both
the development and progression of AD. We believe that manipulating
mitochondrial function and cell bioenergetic pathways will ultimately
achieve this goal.
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